List of Excipients in Branded Drug UBRELVY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	UBRELVY	ubrogepant	0023-6498	CELLULOSE, MICROCRYSTALLINE	2035-01-30
Allergan Inc	UBRELVY	ubrogepant	0023-6498	COPOVIDONE K25-31	2035-01-30
Allergan Inc	UBRELVY	ubrogepant	0023-6498	CROSCARMELLOSE SODIUM	2035-01-30
Allergan Inc	UBRELVY	ubrogepant	0023-6498	MANNITOL	2035-01-30
Allergan Inc	UBRELVY	ubrogepant	0023-6498	SILICON DIOXIDE	2035-01-30

UBRELVY Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

Last updated: August 10, 2026

UBRELVY is AbbVie’s oral ubrogepant product for the acute treatment of migraine with or without aura in adults. Its commercial formulation is a conventional immediate-release film-coated tablet containing lactose-based filler, superdisintegrant, polymeric film-formers, glidant, lubricant, pigments, and coating agents. The strongest excipient opportunities are likely to involve faster disintegration, lactose-free products, orally disintegrating tablets, pediatric-friendly dosage forms, and differentiated solid-state or taste-masked formulations.

UBRELVY’s active ingredient is protected primarily through compound, formulation, and method-of-use rights rather than through a highly differentiated excipient system. The product reached the U.S. market in December 2019, and its five-year new chemical entity exclusivity expired in December 2024. Generic risk now depends principally on Orange Book-listed patents, Paragraph IV activity, patent-term adjustments, settlements, and the ability of an ANDA applicant to match exposure and food-effect performance.

What is UBRELVY and how is it formulated?

UBRELVY contains ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist. It is marketed as 50 mg and 100 mg immediate-release film-coated tablets. The product is administered orally for acute migraine treatment, with a second dose permitted at least two hours after the initial dose, subject to the labeled maximum daily dose. [1]

What excipients are used in UBRELVY tablets?

The UBRELVY tablet uses common pharmaceutical excipients rather than a proprietary delivery platform.

Formulation function	Publicly identified excipient class or material
Diluent and filler	Lactose monohydrate
Disintegration	Croscarmellose sodium
Binder or film-former	Hypromellose and polyvinyl alcohol
Glidant	Colloidal silicon dioxide
Lubricant and coating component	Talc
Opacifier	Titanium dioxide
Plasticizer or coating aid	Polyethylene glycol
Colorant	Iron oxide pigments
Tablet coating	Polymeric film-coating system

The precise quantity of each excipient is not disclosed in the FDA prescribing information. The inactive ingredient list is disclosed in the U.S. product labeling and DailyMed records. [1,2]

The formulation appears designed for manufacturability, mechanical strength, immediate release, and conventional tablet presentation. There is no public indication that UBRELVY uses an extended-release matrix, lipid delivery system, amorphous dispersion, nanocrystal platform, or modified-release coating.

Why do UBRELVY excipients matter commercially?

Excipient selection affects generic approval, manufacturing cost, product differentiation, and the ability to develop alternative dosage forms.

Ubrogepant is a potent, low-dose active ingredient. The 50 mg and 100 mg strengths permit relatively small tablets, which reduces the need for high-load functional excipients. The commercial formulation therefore has room for optimization around disintegration, dissolution, coating performance, and patient acceptability.

The label reports that a high-fat meal delays the time to maximum concentration by approximately two hours and increases exposure, including an increase in maximum concentration. [1] A generic or reformulated product that changes wetting, disintegration, particle size, or solid-state properties could alter the food-effect profile even if the product remains an immediate-release tablet.

Which excipient attributes are most commercially relevant?

The highest-value excipient attributes are:

1. Rapid and reproducible disintegration across both tablet strengths.
2. Consistent dissolution under fed and fasted conditions.
3. Low moisture sensitivity, because moisture can affect tablet hardness and ubrogepant solid-state behavior.
4. Low risk of lactose intolerance or excipient-related patient objections.
5. Reduced tablet weight or improved swallowability.
6. Compatibility with high-speed compression and film coating.
7. A formulation that does not create a materially different food effect.

For generic development, a conventional Q1/Q2-matched tablet is likely to be the lowest-risk pathway. For an innovator or specialty-generic strategy, the commercial value lies in improving administration rather than merely replacing one filler with another.

What formulation opportunities exist for UBRELVY?

Can a lactose-free UBRELVY formulation compete?

A lactose-free tablet is the most straightforward excipient-led opportunity. Lactose monohydrate is a conventional diluent, but a developer could substitute microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler system.

The commercial benefit would be limited for a standard generic because lactose is widely accepted and inexpensive. A lactose-free product could have greater value as a branded authorized generic, patient-preference product, or pharmacy-channel alternative if it preserves bioequivalence and tablet performance.

Potential technical risks include:

• Different compaction behavior.
• Increased tablet weight.
• Changes in disintegration time.
• Different moisture uptake.
• Changes in dissolution after storage.
• Need for new coating and tooling parameters.

Is an orally disintegrating tablet a viable UBRELVY opportunity?

An orally disintegrating tablet, or ODT, is one of the strongest lifecycle opportunities. Migraine patients may experience nausea, vomiting, or difficulty swallowing during an attack. An ODT could improve administration without requiring water.

The core development challenges are taste, dose uniformity, friability, and rapid dissolution. Ubrogepant taste-masking could require polymeric coatings, ion-exchange resins, lipid barriers, cyclodextrins, or multiparticulate technology. Those excipient systems could create new formulation claims, but they could also introduce new patent positions and bioequivalence requirements.

A 50 mg ODT is technically more attractive than a 100 mg ODT because the lower active load allows greater formulation flexibility. A bilayer or dual-strength platform could support both doses while maintaining a common manufacturing process.

Could UBRELVY be developed as a granule, powder, or sprinkle product?

A sachet, oral granule, or sprinkle formulation could target patients who cannot swallow tablets. These dosage forms would require:

• Taste masking.
• Low-dose content uniformity.
• Protection against segregation.
• Moisture-resistant packaging.
• Reproducible dispersion in soft food or liquid.
• Clear administration instructions.

The regulatory pathway could be more complex than a conventional ANDA tablet if the dosage form creates a new route of administration, new administration conditions, or a distinct clinical-use profile. A branded line extension could justify the cost if migraine portfolio revenue remains substantial.

Can excipients improve UBRELVY absorption?

Formulation technologies could target faster dissolution or improved exposure through wetting agents, particle-size engineering, amorphous solid dispersions, cyclodextrin complexes, or lipid-based systems. The commercial rationale is stronger for rapid-onset performance than for increasing total exposure, because the approved product already provides clinically useful oral activity.

A higher-solubility system may reduce variability but could also change the food effect, maximum concentration, or adverse-event profile. Any formulation that materially changes pharmacokinetics would require careful clinical and regulatory assessment.

What patents protect UBRELVY?

UBRELVY protection may include several patent categories:

Patent category	Commercial relevance
Ubrogepant compound patents	Protect the active molecule and related chemical genus
Pharmaceutical composition patents	Cover compositions containing ubrogepant with specified excipients or ratios
Solid-state patents	Protect polymorphs, crystalline forms, salts, solvates, or particle attributes
Manufacturing patents	Cover synthesis, purification, crystallization, or isolation methods
Method-of-use patents	Cover treatment of migraine, dosing schedules, or patient populations
Formulation patents	May cover immediate-release, taste-masked, ODT, or other dosage forms

The FDA Orange Book is the controlling public source for patents listed against UBRELVY approved products. Patent numbers, expiration dates, pediatric extensions, and any listed use codes should be verified against the current Orange Book entry rather than inferred from broad patent-family databases. [3]

The existence of a formulation patent does not automatically prevent an ANDA launch. A generic applicant may certify Paragraph IV, formulate around the claim, challenge validity or enforceability, or wait for expiration.

What is the Orange Book status of UBRELVY?

UBRELVY is an FDA-approved prescription drug marketed in tablet strengths of 50 mg and 100 mg. It is a small-molecule product, not a biologic. The relevant abbreviated pathway is an ANDA, not a biosimilar application.

The Orange Book should be reviewed for:

• Listed patents assigned to UBRELVY.
• Expiration dates and patent-term adjustments.
• Use codes for migraine treatment or dosing limitations.
• Whether each patent is listed for both strengths.
• Any pediatric exclusivity.
• Whether patents cover the drug substance, product, or method of use.

FDA Orange Book listings do not disclose the identity of Paragraph IV filers. A Paragraph IV certification is usually reflected through FDA notice procedures, litigation filings, or company disclosures rather than through the basic Orange Book table. [3,4]

When did UBRELVY lose market exclusivity?

UBRELVY received FDA approval on December 23, 2019. Because ubrogepant was approved as a new chemical entity, the product received five years of statutory NCE exclusivity, generally extending through December 23, 2024, subject to the FDA’s calculation of the effective date. [1,5]

NCE exclusivity blocked submission of an ANDA containing a Paragraph IV certification during the protected period. It did not eliminate later patent protection. Patent-based entry restrictions can continue after regulatory exclusivity expires.

Milestone	Date or status
FDA approval	December 23, 2019
NCE exclusivity	Approximately five years
NCE exclusivity end	December 2024
Generic pathway after NCE period	ANDA, subject to patent certification
Biosimilar pathway	Not applicable
Commercial dosage forms	50 mg and 100 mg film-coated tablets

What generic entry risks exist for UBRELVY?

The primary generic risks are patent litigation, formulation differences, and the timing of any first ANDA approval.

Paragraph IV challenges

An ANDA applicant may certify that listed patents are invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period after receiving notice, FDA approval can be delayed by a 30-month stay, subject to statutory exceptions and litigation outcomes. [4]

For UBRELVY, the most vulnerable claims would generally be narrow formulation or method-of-use claims that can be designed around. Compound claims, if still enforceable, present a more significant barrier. A generic applicant can also pursue a section viii statement for a patented indication if the proposed label omits the protected use.

Generic launch scenarios

Scenario	Likely commercial effect
No Paragraph IV challenge	Entry waits for relevant patent expiry or settlement date
Paragraph IV with litigation	Approval may be delayed by litigation and statutory stay
Successful invalidity or noninfringement case	Earlier generic entry and rapid price erosion
Settlement with licensed entry	Controlled entry date, possible authorized generic dynamics
Formulation-around product	Potential entry if claims do not cover the alternative formulation
First-filer launch	Possible 180-day exclusivity advantage for the first eligible ANDA

A conventional generic tablet is likely to exert the greatest price pressure because it competes directly with the existing 50 mg and 100 mg presentations. A differentiated ODT, lactose-free tablet, or sprinkle product would compete on convenience and adherence rather than only on price.

What is the biosimilar risk for UBRELVY?

There is no biosimilar risk because UBRELVY contains a chemically synthesized small molecule. The relevant competitors are generic ubrogepant products, other CGRP antagonists, triptans, and branded acute migraine therapies.

The competitive class includes Nurtec ODT, containing rimegepant, and QULIPTA, also containing ubrogepant but approved for preventive migraine treatment. A generic UBRELVY product would compete most directly with acute-use gepants, while an ODT or rapid-dissolve ubrogepant product could compete with Nurtec ODT on administration and patient preference.

How does UBRELVY compare with competing migraine products?

Product	Active ingredient	Primary use	Dosage-form advantage
UBRELVY	Ubrogepant	Acute migraine treatment	Conventional 50 mg and 100 mg tablets
Nurtec ODT	Rimegepant	Acute and preventive migraine treatment	Orally disintegrating tablet
QULIPTA	Atogepant	Preventive migraine treatment	Oral tablets
Triptans	Various	Acute migraine treatment	Established, low-cost generic class

UBRELVY’s largest excipient-led vulnerability is the absence of an ODT or other administration format in its primary marketed presentation. Nurtec ODT has already established patient and prescriber familiarity with orally disintegrating CGRP therapy. A UBRELVY ODT could therefore support lifecycle management, but it would need a strong taste-masking and rapid-disintegration profile.

What commercial opportunities exist for excipient suppliers?

Excipient companies can pursue UBRELVY-related opportunities in four areas.

High-value excipient platforms

• Co-processed direct-compression excipients for smaller, stronger tablets.
• Superdisintegrant systems optimized for rapid release.
• Taste-masking polymers and ion-exchange resins for ODT or granules.
• Low-moisture excipients for stability-sensitive solid forms.
• Lactose-free filler-binder systems.
• Film-coating systems that reduce swallowability problems.
• Amorphous dispersion carriers or wetting systems for dissolution enhancement.

Contract development and manufacturing

CDMOs can offer value through:

• Generic formulation development.
• Design-of-experiments studies for disintegration and dissolution.
• Fed-versus-fasted pharmacokinetic bridging.
• High-speed compression scale-up.
• ODT manufacturing.
• Sachet and stick-pack filling.
• Moisture-barrier packaging.

The most defensible opportunity is not an individual excipient substitution. It is an integrated platform that links excipient selection, process parameters, stability, dissolution, and bioequivalence.

How strong is the UBRELVY patent estate?

The estate is commercially relevant because UBRELVY remains a high-value branded migraine product after NCE exclusivity expiry. Its strength depends on the remaining enforceable patent claims, the breadth of any compound protection, the presence of Orange Book-listed formulation patents, and the ability of generic applicants to design around those claims.

A conventional tablet is generally easier to develop around than a patented ODT or advanced delivery system. If AbbVie adds a differentiated dosage form, it could extend commercial differentiation but may also create a new generic target. Patent strength should be assessed claim by claim, with separate analysis of claim scope, priority, written description, enablement, prosecution history, terminal disclaimers, and Orange Book listing status.

What revenue exposure could generic UBRELVY create?

UBRELVY has become a major AbbVie neuroscience product. AbbVie reported approximately $1 billion in annual UBRELVY revenue in the mid-2020s, making generic entry commercially material to the company’s migraine portfolio. [6]

A first generic tablet could produce:

• Rapid gross-to-net pressure.
• Pharmacy substitution.
• Payer step-edit changes.
• Reduced branded prescription volume.
• Lower co-pay support efficiency.
• Pressure on wholesale acquisition price.

An ODT, lactose-free product, or pediatric-oriented product could preserve a branded niche, but these products would not fully insulate the conventional tablet franchise from generic substitution.

Key Takeaways

• UBRELVY contains ubrogepant in 50 mg and 100 mg immediate-release film-coated tablets.
• Its excipient system is conventional and includes lactose monohydrate, croscarmellose sodium, polymeric coating materials, silicon dioxide, talc, titanium dioxide, polyethylene glycol, and iron oxide pigments.
• NCE exclusivity ended in December 2024, leaving patent protection and ANDA litigation as the main timing variables.
• The strongest excipient opportunities are ODT, taste-masked, lactose-free, granule, sprinkle, and rapid-disintegration formulations.
• UBRELVY has generic risk, not biosimilar risk.
• The largest commercial opportunity for excipient and CDMO suppliers is an integrated rapid-release or taste-masked platform that maintains bioequivalence and controls the food effect.
• Current Orange Book entries and litigation records should control any definitive patent-expiry or Paragraph IV conclusion.

FAQs

Can a generic UBRELVY tablet use different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the formulation meets FDA requirements, demonstrates pharmaceutical equivalence and bioequivalence, and does not infringe enforceable patent claims.

Is lactose monohydrate essential to UBRELVY performance?

No. Lactose is a conventional filler and is not inherently required for ubrogepant delivery. Substitution could still affect compression, disintegration, dissolution, stability, and bioequivalence.

Would an UBRELVY ODT require new patents?

An ODT could be protected by new formulation, taste-masking, manufacturing, or solid-state patents. Patentability would depend on the claimed technology and prior art.

Could an excipient change avoid an UBRELVY formulation patent?

Possibly. A formulation patent may require specific excipients, concentrations, ratios, or performance parameters. A non-infringing alternative must be assessed against every asserted claim.

Which competing product creates the greatest formulation pressure?

Nurtec ODT creates the clearest formulation pressure because it offers an orally disintegrating CGRP-antagonist dosage form for acute migraine treatment.

References

1. U.S. Food and Drug Administration. (2019). UBRELVY (ubrogepant) tablets, prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: UBRELVY-ubrogepant tablet, film coated.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.
5. U.S. Food and Drug Administration. (n.d.). New chemical entity exclusivity and generic drug approval provisions.
6. AbbVie Inc. (2025). Annual report for fiscal year 2024.